Post-autologous stem cell transplantation care in Hodgkin Lymphoma with high risk of relapse

Author: Dr. Joanne Britto, McMaster University
Reviewer: Dr. Amaris Balitsky, Assistant Professor, Department of Oncology, McMaster

Objectives

At the end of the self-assessment module, participants will be able to:

1. Describe the available treatment options to improve post-autologous stem cell transplantation outcomes for patients with Hodgkin lymphoma.
2. Describe the approved indications for use of brentuximab vedotin in Canada and the evidence that supports its use.
3. Describe the mechanism of action and common toxicities of brentuximab vedotin.

CHS Scientific Planning Committee Members (2021-22)

Dr. Joanne Britto – Resident Physician, Hematology-Oncology
Dr. Yan Xu – Fellow Physician, Hematology
Dr. Siraj Mithoowani – Clinical Hematologist at St. Joseph’s Healthcare, Hamilton
Dr. Hassan Sibai – Assistant Professor of Medicine, Faculty of Medicine, University of Toronto and Staff Physician, Division of Medical Hematology & Oncology, Princess Margaret Cancer Centre

Conflicts of Interest: None